(44 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
<meta name="keywords" content="iGEM, NTU, Singapore, ModVision"> | <meta name="keywords" content="iGEM, NTU, Singapore, ModVision"> | ||
<meta name="description" content=""> | <meta name="description" content=""> | ||
− | <meta name="viewport" content="width=device-width, initial-scale=1.0 | + | <meta name="viewport" content="width=device-width, initial-scale=1.0"> |
<link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Team:NTU-Singapore/Test_Page/BootstrapCSS&action=raw&ctype=text/css"> | <link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Team:NTU-Singapore/Test_Page/BootstrapCSS&action=raw&ctype=text/css"> | ||
Line 17: | Line 17: | ||
<script src="https://2018.igem.org/wiki/index.php?title=Team:NTU-Singapore/Test_Page/BlocsJS&action=raw&ctype=text/javascript"></script> | <script src="https://2018.igem.org/wiki/index.php?title=Team:NTU-Singapore/Test_Page/BlocsJS&action=raw&ctype=text/javascript"></script> | ||
<script src="https://2018.igem.org/wiki/index.php?title=Team:NTU-Singapore/Test_Page/LazyJS&action=raw&ctype=text/javascript" defer></script> | <script src="https://2018.igem.org/wiki/index.php?title=Team:NTU-Singapore/Test_Page/LazyJS&action=raw&ctype=text/javascript" defer></script> | ||
+ | |||
<title>Home</title> | <title>Home</title> | ||
Line 28: | Line 29: | ||
#home_logo, #sideMenu { display:none; } | #home_logo, #sideMenu { display:none; } | ||
#sideMenu, #top_title, .patrollink {display:none;} | #sideMenu, #top_title, .patrollink {display:none;} | ||
− | #content { width:100%; padding:0px; margin-top:- | + | #content { width:100%; padding:0px; margin-top:-20px; margin-left:0px;} |
body {background-color:white; } | body {background-color:white; } | ||
#bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; } | #bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; } | ||
Line 54: | Line 55: | ||
</div> | </div> | ||
<div class="collapse navbar-collapse navbar-1 nav-special sidebar-nav"> | <div class="collapse navbar-collapse navbar-1 nav-special sidebar-nav"> | ||
− | <ul class="site-navigation nav navbar-nav pull-right nav-margin object-hidden"> | + | <ul class="site-navigation nav navbar-nav pull-right nav-margin object-hidden "> |
<li> | <li> | ||
<a href="index.html">Home</a> | <a href="index.html">Home</a> | ||
Line 63: | Line 64: | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
<li> | <li> | ||
− | <a href="index.html">Team | + | <a href="index.html">Our Team</a> |
</li> | </li> | ||
<li> | <li> | ||
Line 76: | Line 77: | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
<li> | <li> | ||
− | <a href="index.html"> | + | <a href="index.html">DNA Editor</a> |
</li> | </li> | ||
<li> | <li> | ||
− | <a href="index.html"> | + | <a href="index.html">REPAIR</a> |
</li> | </li> | ||
<li> | <li> | ||
− | <a href="index.html"> | + | <a href="index.html">Nanopore</a> |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</li> | </li> | ||
<li> | <li> | ||
Line 107: | Line 96: | ||
</ul> | </ul> | ||
</div> | </div> | ||
+ | </li> | ||
+ | <li> | ||
+ | <a href="interlab-measurement.html">InterLab</a> | ||
</li> | </li> | ||
<li> | <li> | ||
Line 120: | Line 112: | ||
<li> | <li> | ||
<a href="index.html">Composite Parts</a> | <a href="index.html">Composite Parts</a> | ||
− | |||
− | |||
− | |||
</li> | </li> | ||
</ul> | </ul> | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
</li> | </li> | ||
<li> | <li> | ||
Line 151: | Line 137: | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
<li> | <li> | ||
− | <a href="index.html"> | + | <a href="index.html">Metal Criteria</a> |
+ | </li> | ||
+ | <li> | ||
+ | <a href="index.html">Best Human Practice</a> | ||
</li> | </li> | ||
</ul> | </ul> | ||
Line 164: | Line 153: | ||
</div> | </div> | ||
<div class="container"> | <div class="container"> | ||
− | <div class="row picture-margin "> | + | <div class="row picture-margin"> |
<div class="col-sm-12"> | <div class="col-sm-12"> | ||
<img src="img/lazyload-ph.png" data-src="https://static.igem.org/mediawiki/2018/3/3e/T--NTU-Singapore--Logo_Eye.png" class="center-block mg-sm hero-break img-responsive lazyload" width="500" srcset="img/Eye%20Structure.png 2x, img/Eye%20Structure.png 3x" /><img src="img/lazyload-ph.png" data-src="https://static.igem.org/mediawiki/2018/2/2b/T--NTU-Singapore--Logo.png" class="center-block mg-lg img-responsive logo-break lazyload" width="218" height="38" /> | <img src="img/lazyload-ph.png" data-src="https://static.igem.org/mediawiki/2018/3/3e/T--NTU-Singapore--Logo_Eye.png" class="center-block mg-sm hero-break img-responsive lazyload" width="500" srcset="img/Eye%20Structure.png 2x, img/Eye%20Structure.png 3x" /><img src="img/lazyload-ph.png" data-src="https://static.igem.org/mediawiki/2018/2/2b/T--NTU-Singapore--Logo.png" class="center-block mg-lg img-responsive logo-break lazyload" width="218" height="38" /> | ||
− | <h1 class="text-center | + | <h1 class="text-center hero-bloc-text mg-md tc-white "> |
− | + | A CRISPR/Cas Base-Editing Toolkit | |
</h1> | </h1> | ||
<h3 class="text-center mg-lg hero-bloc-text-sub tc-white "> | <h3 class="text-center mg-lg hero-bloc-text-sub tc-white "> | ||
Line 199: | Line 188: | ||
<div class="col-sm-6 col-sm-pull-6"> | <div class="col-sm-6 col-sm-pull-6"> | ||
<h2 class="mg-lg tc-black text-left"> | <h2 class="mg-lg tc-black text-left"> | ||
− | + | A Continuation and Beyond. | |
</h2> | </h2> | ||
<h3 class=" mg-md text-left"> | <h3 class=" mg-md text-left"> | ||
CRISPR/Cas9 DNA Base Editor | CRISPR/Cas9 DNA Base Editor | ||
</h3> | </h3> | ||
− | <p class=" mg-lg text- | + | <p class=" mg-lg text-justify"> |
With the successful truncated dCas9-mediated transcriptional activation last year, we moved further this year into DNA base editing using CRISPR/Cas9 system. We also improved our truncated dCas9 further with novel strategies for higher binding efficiency. | With the successful truncated dCas9-mediated transcriptional activation last year, we moved further this year into DNA base editing using CRISPR/Cas9 system. We also improved our truncated dCas9 further with novel strategies for higher binding efficiency. | ||
</p><a href="index.html" class="btn btn-wire btn-rd pull-left btn-lg">Project Improve</a> | </p><a href="index.html" class="btn btn-wire btn-rd pull-left btn-lg">Project Improve</a> | ||
Line 232: | Line 221: | ||
Human-Centred Research | Human-Centred Research | ||
</h2> | </h2> | ||
− | <p class="mg-lg text- | + | <p class="mg-lg text-justify"> |
Our research involves not only the students and scientists, but also the Singapore public. While doing our project, we looked into the public opinions towards gene editing. Our human practice tells how our project evolved around the local community that we live in. | Our research involves not only the students and scientists, but also the Singapore public. While doing our project, we looked into the public opinions towards gene editing. Our human practice tells how our project evolved around the local community that we live in. | ||
</p><a href="index.html" class="btn btn-wire btn-rd">Integrated Human Practice</a> | </p><a href="index.html" class="btn btn-wire btn-rd">Integrated Human Practice</a> | ||
Line 263: | Line 252: | ||
CRISPR/Cas13b RNA Base Editor | CRISPR/Cas13b RNA Base Editor | ||
</h3> | </h3> | ||
− | <p class="mg-lg text- | + | <p class="mg-lg text-justify"> |
As we have learnt through our interviews with medical doctors and interaction with the public, it is evident that RNA editing is more promising and better accep-ted in our society. Hence, we reflected on our project and ventured into RNA editing. | As we have learnt through our interviews with medical doctors and interaction with the public, it is evident that RNA editing is more promising and better accep-ted in our society. Hence, we reflected on our project and ventured into RNA editing. | ||
</p><a href="index.html" class="btn btn-wire btn-rd pull-left">Project REPAIR</a> | </p><a href="index.html" class="btn btn-wire btn-rd pull-left">Project REPAIR</a> | ||
Line 295: | Line 284: | ||
Modification-Sensitive Nanopore Sequencing | Modification-Sensitive Nanopore Sequencing | ||
</h3> | </h3> | ||
− | <p class="mg-lg "> | + | <p class="mg-lg text-justify"> |
To address the significant concern around the safety of RNA editing technology, we designed an unbiased, accurate RNA sequencing tool. Expanding the nanopore sequencing platform, we hope to enhance the saftey of RNA editing. | To address the significant concern around the safety of RNA editing technology, we designed an unbiased, accurate RNA sequencing tool. Expanding the nanopore sequencing platform, we hope to enhance the saftey of RNA editing. | ||
</p><a href="index.html" class="btn btn-wire btn-rd pull-left">Project Nanopore</a> | </p><a href="index.html" class="btn btn-wire btn-rd pull-left">Project Nanopore</a> | ||
Line 311: | Line 300: | ||
</div> | </div> | ||
<!-- Main container END --> | <!-- Main container END --> | ||
+ | |||
+ | |||
+ | <!-- Preloader --> | ||
+ | <div id="page-loading-blocs-notifaction"></div> | ||
+ | <!-- Preloader END --> | ||
</body> | </body> | ||
</html> | </html> |
Latest revision as of 17:37, 23 September 2018
A CRISPR/Cas Base-Editing Toolkit
From Genome to Transcriptome, From Detection to Modification.
A Continuation and Beyond.
CRISPR/Cas9 DNA Base Editor
With the successful truncated dCas9-mediated transcriptional activation last year, we moved further this year into DNA base editing using CRISPR/Cas9 system. We also improved our truncated dCas9 further with novel strategies for higher binding efficiency.
Project ImproveHuman-Centred Research
Our research involves not only the students and scientists, but also the Singapore public. While doing our project, we looked into the public opinions towards gene editing. Our human practice tells how our project evolved around the local community that we live in.
Integrated Human PracticeAdapt to Change.
CRISPR/Cas13b RNA Base Editor
As we have learnt through our interviews with medical doctors and interaction with the public, it is evident that RNA editing is more promising and better accep-ted in our society. Hence, we reflected on our project and ventured into RNA editing.
Project REPAIRAim Even Higher.
Modification-Sensitive Nanopore Sequencing
To address the significant concern around the safety of RNA editing technology, we designed an unbiased, accurate RNA sequencing tool. Expanding the nanopore sequencing platform, we hope to enhance the saftey of RNA editing.
Project Nanopore